SCHEMBL12640273

SCHEMBL12640273

COc1cnc2c(c1)c(I)cn2C

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MTNR1A P48039 2/20 0.50
BRD4 O60885 1/20 0.48
HASPIN Q8TF76 1/20 0.41
HSP90AA1 P07900 1/20 0.34
HSP90AB1 P08238 1/20 0.34
PDK1 Q15118 1/20 0.34
ACVR2A P27037 1/20 0.33
TGFBR2 P37173 1/20 0.33
MAOB P27338 3/20 0.31
AAK1 Q2M2I8 1/20 0.31
ADRB2 P07550 1/20 0.31
GSK3A P49840 3/20 0.31
GSK3B P49841 3/20 0.31
AURKB Q96GD4 3/20 0.31
LCK P06239 2/20 0.31
IGF1R P08069 2/20 0.31
CDK7 P50613 2/20 0.31
LRRK2 Q5S007 2/20 0.31
JAK2 O60674 1/20 0.31
BTK Q06187 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12304411 0.82 MTNR1A (0.38) MTNR1ABRD4ACVR2ATGFBR2MAOB
SCHEMBL31370659 0.80 MTNR1A (0.50) MTNR1ABRD4HSP90AA1HSP90AB1PDK1
SCHEMBL24916102 0.80 MTNR1A (0.39) MTNR1ABRD4ACVR2ATGFBR2MAPT
SCHEMBL29923703 0.80 MTNR1A (0.39) MTNR1ABRD4ACVR2ATGFBR2MAPT
SCHEMBL24915549 0.78 MTNR1A (0.48) MTNR1AHSP90AA1HSP90AB1PDK1ACVR2A
SCHEMBL17211632 0.77 BRD4 (0.55) MTNR1ABRD4HASPIN
SCHEMBL1892537 0.77 MTNR1A (0.35) MTNR1ABRD4ACVR2ATGFBR2
SCHEMBL8126470 0.76 ALDH1A1 (0.52) MTNR1AACVR2ATGFBR2GSK3BMAPT
SCHEMBL24331224 0.76 BRD4 (0.50) BRD4HASPINHSP90AA1PDK1GSK3B
SCHEMBL22554076 0.76 BRD4 (0.50) BRD4HASPINGSK3BCDK5DYRK1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4055013-B1 WDR5 INHIBITORS AND MODULATORS UNIV VANDERBILT (US) 2024-03-20 EP disclosed
US-20230026466-A1 WDR5 INHIBITORS AND MODULATORS VANDERBILT UNIVERSITY 2023-01-26 US disclosed
US-20230026466-A1 WDR5 INHIBITORS AND MODULATORS VANDERBILT UNIVERSITY 2023-01-26 US disclosed
EP-4055013-A1 WDR5 INHIBITORS AND MODULATORS Vanderbilt University (US) 2022-09-14 EP disclosed
US-9096593-B2 Compounds and methods for kinase modulation, and indications therefor PLEXXIKON INC. (US) 2015-08-04 US disclosed
US-20140045840-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR PLEXXIKON INC. (US) 2014-02-13 US disclosed
US-20110112127-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR PLEXXIKON, INC. 2011-05-12 US disclosed
US-20100035878-A1 INHIBITORS OF C-JUN N-TERMINAL KINASES FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS RELATING TO APOPTOSIS AND/OR INFLAMMATION EISAI R & D MANAGEMENT CO., LTD. (JP) 2010-02-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100035878-A1 INHIBITORS OF C-JUN N-TERMINAL KINASES FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS RELATING TO APOPTOSIS AND/OR INFLAMMATION NFKBIA, CHUK, MAP3K1 MTNR1A 1487/4885BRD4 1290/4885HASPIN 502/4885
US-20110112127-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR KIT, FLT3, BRAF MTNR1A 1804/4885BRD4 3163/4885HASPIN 242/4885
US-20230026466-A1 WDR5 INHIBITORS AND MODULATORS WDR5, WDR1, WDR3 MTNR1A 3776/4885BRD4 33/4885HASPIN 688/4885
US-20140045840-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR KIT, FLT3, BRAF MTNR1A 1804/4885BRD4 3163/4885HASPIN 242/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.